Primary-source record
Decision-gradeAdvisory committee scheduled
Dermatologic and Ophthalmic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-New Drug Application (NDA) 219694 for Atropine Sulfate Ophthalmic Solution, 0.01%
The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.
Key facts
- Filed
- Sep 25, 2026, 12:00 AM
- Event
- Advisory committee scheduled
- Direction
- Neutral
- Company
LGNDLigand- Asset
- atropine
- Source
- Federal Register
- Confidence
- Sourced
- Calendar
- Advisory committee · Sep 25, 2026 · Outcome not recorded
Source excerpt
The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee (the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.